{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:49:44Z","timestamp":1793908184022,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhepr.2024.101295","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T17:24:27Z","timestamp":1733419467000},"page":"101295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-5152","authenticated-orcid":false,"given":"Simon Johannes","family":"Gairing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7367-1708","authenticated-orcid":false,"given":"Philipp","family":"Mildenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-9720","authenticated-orcid":false,"given":"Fabian","family":"Artusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-5133","authenticated-orcid":false,"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Leyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-8833","authenticated-orcid":false,"given":"Friedrich","family":"Sinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"J\u00f6rg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorben","family":"Fruendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Himmelsbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cennet","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4154-8270","authenticated-orcid":false,"given":"Katrin","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Schuhbaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Labuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-5466","authenticated-orcid":false,"given":"James","family":"Korolewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A.M.","family":"Fulgenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-3671","authenticated-orcid":false,"given":"Antonio","family":"D'Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-6601","authenticated-orcid":false,"given":"Valentina","family":"Zanuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Hucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6653-8765","authenticated-orcid":false,"given":"Natascha","family":"R\u00f6hlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Ben Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2015-4682","authenticated-orcid":false,"given":"Eleonora","family":"Ramadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-1716","authenticated-orcid":false,"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-4792","authenticated-orcid":false,"given":"Roman","family":"Kloeckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-0621","authenticated-orcid":false,"given":"Peter Robert","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-6489","authenticated-orcid":false,"given":"Nguyen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar K.","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Teufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-8207","authenticated-orcid":false,"given":"Enrico N.","family":"De Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Thomas","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-2682","authenticated-orcid":false,"given":"Jens U.","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-8729","authenticated-orcid":false,"given":"Dominik","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-2728","authenticated-orcid":false,"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-1456","authenticated-orcid":false,"given":"Florian P.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1409-7697","authenticated-orcid":false,"given":"Christoph","family":"Roderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ettrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Scheble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-1953","authenticated-orcid":false,"given":"Ursula","family":"Ehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Luise","family":"Berres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Gonzalez-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelius","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-0974","authenticated-orcid":false,"given":"Marino","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-0672","authenticated-orcid":false,"given":"Florian","family":"van B\u00f6mmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4522-9343","authenticated-orcid":false,"given":"Leonie S.","family":"Jochheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-4275","authenticated-orcid":false,"given":"Raphael","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-3003","authenticated-orcid":false,"given":"Sumera I.","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schmidtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-8891","authenticated-orcid":false,"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101295_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2024.101295_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3 Suppl","key":"10.1016\/j.jhepr.2024.101295_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo)\u00a0+ bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101295_bib4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101295_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: an EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib7","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101295_bib8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/liv.14220","article-title":"The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma","volume":"39","author":"Sanghera","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2024.101295_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach - the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101295_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib11","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.3390\/cancers14235834","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2024.101295_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000506293","article-title":"Nutritional index as prognostic indicator in patients receiving lenvatinib treatment for unresectable hepatocellular carcinoma","volume":"98","author":"Hiraoka","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2024.101295_bib13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.21.02373","article-title":"Breaking the Child-Pugh dogma in hepatocellular carcinoma","volume":"40","author":"Johnson","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101295_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17474124.2020.1748010","article-title":"ALBI versus Child-Pugh in predicting outcome of patients with HCC: a systematic review","volume":"14","author":"Peng","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib16","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jgh.13291","article-title":"Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma","volume":"31","author":"Chan","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000529996","article-title":"Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: a post hoc analysis of the phase III IMbrave150 study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2024.101295_bib18","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.annonc.2022.04.446","article-title":"O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2024.101295_bib19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1159\/000516490","article-title":"Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma","volume":"10","author":"Vogel","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2024.101295_bib20","doi-asserted-by":"crossref","first-page":"ix45","DOI":"10.1093\/annonc\/mdz422.005","article-title":"Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2024.101295_bib21","article-title":"Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2","volume":"3","author":"Kudo","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2024.101295_bib22","article-title":"ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma","volume":"3","author":"Demirtas","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2024.101295_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1159\/000508971","article-title":"EZ-ALBI score for predicting hepatocellular carcinoma prognosis","volume":"9","author":"Kariyama","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2024.101295_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000488778","article-title":"Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2024.101295_bib25","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.3390\/cancers14205083","article-title":"Modified albumin-bilirubin model for stratifying survival in patients with hepatocellular carcinoma receiving anticancer therapy","volume":"14","author":"Hsu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2024.101295_bib26","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1002\/cam4.5495","article-title":"New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a validation study","volume":"12","author":"Tada","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhepr.2024.101295_bib27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2012.06.022","article-title":"A\u00a0novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI)","volume":"57","author":"Pinato","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000528818","article-title":"Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"101","author":"Rimini","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2024.101295_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000527676","article-title":"Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma\u00a0treated with atezolizumab plus bevacizumab","volume":"101","author":"Tada","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2024.101295_bib30","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/bjc.2012.92","article-title":"A\u00a0novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)","volume":"106","author":"Pinato","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2024.101295_bib31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MEG.0000000000002356","article-title":"Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis","volume":"34","author":"Tada","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/cancers14020343","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2024.101295_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/hepr.13836","article-title":"Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma","volume":"53","author":"Ochi","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2024.101295_bib34","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.3390\/curroncol28050352","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma","volume":"28","author":"Eso","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jhepr.2024.101295_bib35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/apt.17441","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort","volume":"57","author":"Jost-Brinkmann","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2024.101295_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2024.101295_bib37","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2024.101295_bib38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2022.02.021","article-title":"Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score","volume":"77","author":"\u00c5berg","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib39","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.csda.2011.02.004","article-title":"Practical variable selection for generalized additive models","volume":"55","author":"Marra","year":"2011","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.jhepr.2024.101295_bib40","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing\u00a0time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2024.101295_bib41","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2024.101295_bib42","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2021.01.023","article-title":"Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival","volume":"74","author":"Bettinger","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101295_bib43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101295_bib44","first-page":"1899","article-title":"Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma","volume":"12","author":"Teng","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jhepr.2024.101295_bib45","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1002\/cam4.5294","article-title":"The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab:\u00a0a multicenter retrospective analysis","volume":"12","author":"Hatanaka","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhepr.2024.101295_bib46","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.21873\/anticanres.16310","article-title":"Identification of atezolizumab plus bevacizumab prognostic index via recursive partitioning analysis in HCC: the ABE index","volume":"43","author":"Persano","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhepr.2024.101295_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000519448","article-title":"Early changes in alpha-fetoprotein are\u00a0a useful predictor of efficacy of atezolizumab plus bevacizumab treatment\u00a0in patients with advanced hepatocellular carcinoma","volume":"100","author":"Kuzuya","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2024.101295_bib48","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41416-023-02334-7","article-title":"Trajectories of \u03b1-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study","volume":"129","author":"Lu","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2024.101295_bib49","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/liv.15487","article-title":"Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab","volume":"43","author":"Campani","year":"2023","journal-title":"Liver Int"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:29:01Z","timestamp":1741638541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924002994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2589555924002994"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101295","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101295"}}